Hodgkin Lymphoma

From WikiLectures

Hodgkin lymphoma, or malignant lymphogranuloma, is a cancer of the lymphatic tissue. The exact etiology is unknown (genetic predisposition, immune disorder, EBV, HIV). It is most often diagnosed between the ages of 20 and 30 and after the age of 50. The disease emerges in the Lymph node (most often in axial lymph nodes), from where it it spread to neighboring lymph nodes as well as to the systemic circulation.

Histologically, they are divided according to the number of Reed-Sternberg cells (cells formed by mutated B-cell) and according to the degree of cellular response.

  • type I is also known as lymphocyte-rich HL with predominant lymphocytes (few RS cells with many lymphocytes; best prognosis) (5%);
  • type II is also known as nodular sclerosing Hodgkin lymphoma (NSHL) (nodular foci with reticular cells, lymphocytes and histiocytes surrounded by collagens) (70%);
  • type III is also known as mixed cellularity type (20-25%);
  • type IV is also known as lymphocyte-depleted HL with small populations of lymphocytes (abundant proliferated RS cells; worst prognosis) (1%).

Clinical Manifestation[edit | edit source]

Diagnostics[edit | edit source]

  • Nodular extirpation and its subsequent histopathological examination - the presence of RS cells or Hodgkin's cell (RS cell precursors)
  • Chest X-ray, abdominal ultrasound, scintigraphy of liver, spleen, CT and lymphography, PET;
  • Trepanobiopsy of bone marrow.

Stages[edit | edit source]

Mikroskopický obraz Hodgkinova lymfomu
  • Stage I (involvement of single lymph node region or one extra-lymphatic organ);
  • Stage II (involvement of 2 or more lymph node regions on a same side of diaphragm);
  • Stage III (involvement of lymph node on both sides of the diaphragm, including extra-lymphatic organ or spleen);
  • Stage IV (disseminated involvement of extra-lymphatic organs independent of nodal involvement).

Each stages are further divided into A and B:

  • A- the patient is without systemic symptoms;
  • B - the patient is with systemic symptoms (weight loss of 10% in 6 months, fever more than 38 ° C, night sweats).

Complications[edit | edit source]

  • Infections, spinal cord compression when the vertebrae are affected.

Therapy[edit | edit source]

The basic treatment method is systemic treatment by a combined chemotherapy, in localized stages radiotherapy is used to supplement. Basic regimens used are: ABVD (adriamycin, bleomycin, vinblastine, decarbazine), BEACOPP (bleomycin, stoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone).

  • Localized (early) stages I, II: 2 × ABVD and radiotherapy 20 Gy with favorable prognosis (without risk factors). 2×BEACOPP + 2×ABVD and radiotherapy 20 Gy with unfavorable prognosis (with risk factors)
  • Advanced stages III, IV: 6×BEACOPP escalated mode
  • In recurrent cases - rescue regimen (based on platinum derivatives), autologous transplantation.
  • New drugs - brentuximab vedotin (anti-CD30 antibody) is used to treat recurrent HL. [1]

Prognosis[edit | edit source]

Patients have a good prognosis, about 70-80% of patients recover. The tumor is curable.

Links[edit | edit source]

Související články[edit | edit source]

Reference[edit | edit source]

  1. ČEŠKA, Richard, et al. Interna. 2. edition. Praha : Triton, 2015. 909 pp. ISBN 978-80-7387-895-5.

Bibliography[edit | edit source]

  • ČEŠKA, Richard, et al. Interna. 2. edition. Praha : Triton, 2015. 909 pp. ISBN 978-80-7387-895-5.
  • KLENER, Pavel, et al. Vnitřní lékařství. 4. edition. Praha : Galén, Karolinum, 2011. 1174 pp. ISBN 978-80-7262-705-9.


Classifications and references[edit | edit source]